Author

S. D. Schmidt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:multiome· 1 Organism:non-human primate· 1

Frequent Co-Authors

L. Wang· 4 shared S. O'Dell· 4 shared W. Shi· 4 shared E. S. Yang· 3 shared N. A. Doria-Rose· 3 shared Y. Zhang· 3 shared A. Pegu· 2 shared A. R. Henry· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

L. Wang

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant

S. M. Scheaffer, D. Lee, B. Whitener, B. Ying, K. Wu, H. Jani, P. Martin, N. J. Amato, L. E. Avena, D. M. Berrueta, S. D. Schmidt, S. O'Dell, A. Nasir, G.-Y. Chuang, G. Stewart-Jones, , M. S. Diamond

This study evaluates bivalent SARS-CoV-2 mRNA vaccines and finds they induce broader neutralizing antibodies and better protection against BA.5 Omicron compared to monovalent vaccines.

bioRxiv · Sep 12, 2022 · PreprintMicrobiology

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

N. S. Lima, M. Musayev, T. S. Johnston, D. A. Wagner, A. R. Henry, L. Wang, E. S. Yang, Y. Zhang, K. Birungi, W. P. Black, S. O'Dell, S. D. Schmidt, D. Moon, C. G. Lorang, B. Zhao, , P. D. Kwong

The paper examines antibody responses to SARS-CoV-2 variants, finding convergent epitope specificities, V gene usage, and public B cell clones across different variants.

bioRxiv · Mar 28, 2022Immunology

Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates

K. S. Corbett, M. Gagne, D. Wagner, S. O'Connell, S. R. Narpala, D. R. Flebbe, S. F. Andrew, R. L. Davis, B. Flynn, T. S. Johnston, C. Stringham, L. Lai, D. Valentin, A. Van Ry, Z. Flinchbaugh, , A Pekosz

mRNA-1273 boosted nonhuman primates show increased neutralizing antibody responses and protection against SARS-CoV-2 beta variant infection.

bioRxiv · Aug 11, 2021 · PreprintImmunology

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

A. Pegu, S. E. O'Connell, S. D. Schmidt, S. O'Dell, C. A. Talana, L. Lai, J. Albert, E. Anderson, H. Bennett, K. Corbett, B. Flach, L. Jackson, B. Leav, J. E. Ledgerwood, C. J. Luke, , N. A. Doria-Rose

This study assesses the durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants over seven months, finding persistent but reduced binding and functional responses.

bioRxiv · May 13, 2021 · PreprintImmunology

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

K. S. Corbett, D. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-Barnum, R. A. Gillespie, S. Himansu, A. Schafer, C. T. Ziwawo, A. T. DiPiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch, , Wang

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

bioRxiv · Jun 11, 2020Immunology